Comparative Pharmacology
Head-to-head clinical analysis: CLOMID versus EVISTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMID versus EVISTA.
CLOMID vs EVISTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (GnRH) and subsequent LH and FSH release, stimulating ovulation.
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
60 mg orally once daily.
None Documented
None Documented
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator